Efficacy of sirolimus for epileptic seizures in childhood associated with focal cortical dysplasia type II.
Brain Dev
; 45(6): 343-347, 2023 Jun.
Article
em En
| MEDLINE
| ID: mdl-36870920
ABSTRACT
OBJECTIVE:
The efficacy of the mechanistic target of rapamycin inhibitor, sirolimus, was recently reported for patients more than 6 years of age by Kato et al. We evaluated the efficacy and safety of sirolimus in a 2-year-old patient with recurrent focal seizures with impaired consciousness after focal cortical dysplasia (FCD) type IIa resection.METHODS:
The patient was a 2-year-old girl who had recurrent seizures after undergoing FCD resection at 4 months of age. The initial dose of sirolimus was 0.5 mg/day and was gradually increased using the trough blood concentration before oral administration as an index, and evaluation was performed at 92 weeks.RESULTS:
The trough blood level of sirolimus was increased to 6.1 ng/mL and maintenance therapy was started at 40 weeks. Focal seizures with impairment of consciousness with tonic extension of the limbs decreased. No critically serious adverse events occurred.CONCLUSION:
Sirolimus was effective against epileptic seizures from FCD type II even for a child under 5 years of age. There were no critically serious adverse events and administration could be continued.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Epilepsia Generalizada
/
Epilepsia
/
Malformações do Desenvolvimento Cortical
/
Displasia Cortical Focal
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Child
/
Child, preschool
/
Female
/
Humans
Idioma:
En
Revista:
Brain Dev
Ano de publicação:
2023
Tipo de documento:
Article